Educational information, reviewed by Ryan Arvizo, FNP-C. Current as of August 2026. This is general information, not medical advice.
If you’ve been following GLP-1 medications like semaglutide, you’ve probably seen headlines about compounded versions being “banned,” “legal,” or “in a gray area” — sometimes in the same week. The rules genuinely changed in 2025, so here’s a plain-language explanation of where things actually stand.
The short answer
The era of broad, widely-available compounded semaglutide is over. A narrower, patient-specific path still exists in certain circumstances — but it’s a clinical decision made with a licensed provider and filled by a state-licensed pharmacy, not something you buy off a menu.
What changed: the shortage ended
Here’s the key fact almost every confusing headline traces back to. When the FDA officially lists a drug as in shortage, compounding pharmacies are temporarily allowed to prepare their own versions to meet demand. Brand-name semaglutide spent a long stretch on that shortage list — which is why compounded semaglutide became so widely advertised.
The FDA declared the semaglutide shortage resolved in February 2025. Once a shortage ends, the temporary permission to mass-produce compounded copies ends with it.
So can you still get compounded semaglutide?
Sometimes — but the bar is higher and narrower now:
- Mass-produced “copycat” compounding of the commercial product is no longer permitted.
- Patient-specific compounding under Section 503A can still apply in specific situations — for example, when there’s a documented clinical reason the standard commercial product doesn’t fit an individual patient. This is prepared by a state-licensed pharmacy against an individual prescription.
In short: it moved from “widely available” to “case-by-case, provider-directed.”
Why this matters for your safety
As demand outran the rules, the FDA issued warning letters to compounding pharmacies and telehealth sellers, and independent testing has turned up counterfeit and unapproved products — including oral “semaglutide” that isn’t what it claims to be. The single most important safety factor isn’t the word “compounded” — it’s who prepared it. A reputable, state-licensed U.S. pharmacy working under a real prescription and clinical oversight is a very different thing from an unverified online seller.
One more honest note: compounded medications are not FDA-approved, even when prepared by a legitimate pharmacy. That’s true of compounding in general, and a provider should explain it to you before you start.
How BioPeakRx approaches this
Our whole model is built for exactly this kind of shifting landscape:
- Nothing is sold direct-to-cart. Every medication starts with a provider evaluation, and is prescribed only when it’s clinically appropriate for you.
- Anything prescribed is prepared by state-licensed, FDA-registered U.S. pharmacies — never overseas or “research-only” suppliers.
- We track the regulatory status of these medications continuously, so the guidance you get reflects where the rules actually are — not where they were last year.
If a GLP-1 program is right for you, the goal is durable, monitored care — not the cheapest vial you can find online.
Talk to a provider
Whether compounded or brand-name semaglutide fits your situation is a clinical question. A Provider Evaluation is the place to answer it honestly, with the current rules and your health history both on the table.
Sources
- FDA — Bulk drug substances & human drug compounding
- FDA — FDA’s concerns with unapproved GLP-1 drugs used for weight loss
This information is educational and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Compounded medications are not FDA-approved. Treatments require evaluation by a licensed provider.